All In Biotech

Drug Trial Radar · NCT04003142

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 501 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

501

Actual

Start

Jul 10, 2019

Primary completion

Jul 30, 2020

Study completion Apr 23, 2021

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jul 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The study treatments are fezolinetant 30 mg (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study compared fezolinetant and placebo after 4 and 12 weeks of dosing. The study evaluated if fezolinetant reduces the number of hot flashes and the study evaluated if fezolinetant reduces the severity of the hot flashes. Women in the study received an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants used this to record their hot flashes. Their record for the 10 days before the start of study treatment was checked. They remained in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they were picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin. The study participants took study treatment for 52 weeks. The first 12 weeks of study treatment was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo) during that time. The last 40 weeks of study treatment was "noncontrolled." That means that each study participant and the study doctors knew which study treatment that study participant took during that time. Women who took fezolinetant during the first 12 weeks continued to take the same dose. Women who took placebo during the first 12 weeks took fezolinetant. Their dose was either 30 mg or 45 mg fezolinetant. At weeks 2, 4, 8, 12, 14, 16 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine was collected for laboratory tests. Study participants completed questionnaires that were about how hot flashes affect their daily life. Study participants who had their uterus had the following 2 tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. This test used sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic was 3 weeks after the last dose of study treatment.

Conditions

  • Hot Flashes

Interventions

  • FezolinetantDrug

    Oral tablet

  • placeboDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
  2. Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
  3. Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
  4. Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12

Locations

93 sites in 7 countries. Site status is shown where the registry gives one.

  • Mesa Obstetricians and Gynecologists

    Mesa, Arizona

  • Precision Trials

    Phoenix, Arizona

  • Visions Clinical Research - Tuscon

    Tucson, Arizona

  • Excell Research

    Oceanside, California

  • Dream Team Clinical Research, LLC

    Pomona, California

  • Clinical Trials Research

    Sacramento, California

  • Wake Research Associates, LLC

    San Diego, California

  • Women's Healthcare Affiliates

    San Diego, California

  • Bayview Research Group

    Valley Village, California

  • Downtown Women's Health Care

    Denver, Colorado

  • Horizons Clincial Research Center LLC

    Denver, Colorado

  • Physicians' Research Options/Red Rocks OB/GYN

    Lakewood, Colorado

  • Helix Biomedics

    Boynton Beach, Florida

  • Renaissance Research and Medical Group, Inc.

    Cape Coral, Florida

  • Nature Coast Clinical Research

    Crystal River, Florida

  • Bioclinica Research, Melbourne

    Melbourne, Florida

  • LCC Medical Research Institute, LLC

    Miami, Florida

  • Suncoast Clinical Research, Inc.

    Miami, Florida

  • Suncoast Research

    Miami, Florida

  • Medical Health Center & Research

    Miami, Florida

  • Healthcare Clinical Data Inc

    North Miami, Florida

  • Sensible Healthcare LLC

    Ocoee, Florida

  • Bioclinica Research

    Orlando, Florida

  • Ormond Medical Arts Pharmaceutical Research Center

    Ormond Beach, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Physician Care Clinical Research, LLC

    Sarasota, Florida

  • Meridien Research

    St. Petersburg, Florida

  • GCP Clinical Research, LLC

    Tampa, Florida

  • Comprehensive Clinical Development

    West Palm Beach, Florida

  • Clinical Research of Central Florida

    Winter Haven, Florida

  • Georgia Research for Women

    Atlanta, Georgia

  • Agile Clinical Research Trials, LLC

    Atlanta, Georgia

  • iResearch Atlanta LLC

    Decatur, Georgia

  • WR-Mount Vernon Clinical Research

    Sandy Springs, Georgia

  • Georgia Clinical Research

    Snellville, Georgia

  • Elite Clinical Trials

    Blackfoot, Idaho

  • ASR, LLC-Advanced Specialty Research

    Nampa, Idaho

  • Affinity Clinical Research Institute

    Oak Brook, Illinois

  • Cypress Medical Research Center

    Wichita, Kansas

  • Praetorian Pharmaceutical Research

    Marrero, Louisiana

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.